NFKB1 and rheumatoid arthritis: The potential pharmacological mechanism for these effects might be related to the inhibition of inflammatory reactions during the RA process, whereby matrine suppresses the release of pro-inflammatory cytokines and enzymes and inhibits the promotion of proteins in the NF-κB pathway.